5 completed, 1 terminated. 4 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow D-JNKI-1: new trials by email Literature Review of D-JNKI-1 trials Research Report on D-JNKI-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment AM-111 0.4 mg/ml, AM-111 0.8 mg/ml, Placebo - Hearing Loss, Idiopathic Sudden Sensorineural | Phase 3 | Terminated | Auris Medical, Inc. | 56 | 2016-06-01 | 2020-08-07 |
| AM-111 in the Treatment of Acute Inner Ear Hearing Loss Placebo, AM-111 0.4 mg/ml, AM-111 0.8 mg/ml - Hearing Loss | Phase 3 | Completed | Auris Medical AG | 256 | 2015-11-01 | 2023-09-14 |
| Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain XG-102, Placebo - Inflammation, Pain | Phase 3 | Completed | Xigen SA | 309 | 2015-07-01 | 2017-01-24 |
| Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation XG-102, Placebo - Inflammation, Pain | Phase 3 | Completed | Xigen SA | 339 | 2014-09-01 | 2017-01-24 |
| Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers XG-102 - Inflammation | Phase 1 | Completed | Xigen SA | 24 | 2011-07-01 | 2012-04-04 |
| Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss AM-111, placebo - Hearing Loss | Phase 2 | Completed | Auris Medical AG | 210 | 2008-12-01 | 2014-06-26 |
Hearing Loss (3) · Inflammation (3) · Cataract (2) · Deafness (2) · Ear Diseases (2) · Hearing Disorders (2) · Hearing Loss, Sensorineural (2) · Hearing Loss, Unilateral (2) · Otorhinolaryngologic Diseases (2) · Pain (2) · Sensation Disorders (2) · Signs and Symptoms (2) · Speech Disorders (2) · Hearing Loss, Noise-Induced (1) · Hearing Loss, Sudden (1)
Xigen SA (3) · Auris Medical AG (2) · Auris Medical, Inc. (1)
United States (3) · Bulgaria (1) · Canada (1) · Germany (1) · South Korea (1) · Switzerland (1)
Juli Chalifour (1) · Michael Seiberling, MD (1) · Steven M Silverstein, MD (1) · Thomas Meier (1)